<DOC>
	<DOCNO>NCT02098512</DOCNO>
	<brief_summary>Patients relapse refractory Hodgkin Lymphoma CD30+ receive standard care reduce intensity regimen allogeneic stem cell transplant ( another person , relate unrelated ) . Following recovery , patient receive medication call Brentuximab Vendotin target CD30+ cell . The study hypothesis treatment safe well tolerated child young adult .</brief_summary>
	<brief_title>Immunotherapy Following Reduced Intensity Conditioning Allogeneic Stem Cell Transplant Poor Risk CD30+ Hodgkin Lymphoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>45 year age less . Patients Hodgkin Lymphoma either follow : • Primary induction failure ( failure achieve initial CR ) and/or primary refractory disease OR First , Second Third relapse AND History prior ablative auto HSCT ineligible ablative auto HSCT ≥25 % residual disease least two reinduction chemotherapy cycle AND HLA match family donor ( 6/6 5/6 ) match unrelated adult donor ( MUD ) ( 8/8 ) match umbilical cord blood unit ( ≥5/6 ) prethaw cell dose least 3 x 107/kg TNC . investigational therapy one month prior entry study . adequate organ function Patients HD 4th great CR , PR , and/or SD ineligible . Patients rapidly progressive disease ( PD ) unresponsive reinduction chemo , radio , immunotherapy ineligible . Patients n't eligible donor ineligible . Women pregnant ineligible .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Brentuximab Vedotin</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Relapsed Hodgkin Lymphoma</keyword>
	<keyword>Refractory Hodgkin Lymphoma</keyword>
	<keyword>Reduced Intensity Conditioning</keyword>
	<keyword>Allogeneic Stem Cell Transplantation</keyword>
</DOC>